解决生物医学研究中资助偏见和利益冲突的政策机制研究:范围审查。

IF 7.2 Q1 ETHICS
S Scott Graham, Quinn Grundy, Nandini Sharma, Jade Shiva Edward, Joshua B Barbour, Justin F Rousseau, Zoltan P Majdik, Lisa Bero
{"title":"解决生物医学研究中资助偏见和利益冲突的政策机制研究:范围审查。","authors":"S Scott Graham, Quinn Grundy, Nandini Sharma, Jade Shiva Edward, Joshua B Barbour, Justin F Rousseau, Zoltan P Majdik, Lisa Bero","doi":"10.1186/s41073-025-00164-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Industry funding and author conflicts of interest (COI) have been consistently shown to introduce bias into agenda-setting and results-reporting in biomedical research. Accordingly, maintaining public trust, diminishing patient harm, and securing the integrity of the biomedical research enterprise are critical policy priorities. In this context, a coordinated and methodical research effort is required to effectively identify which policy interventions are most likely to mitigate against the risks of funding bias. Subsequently this scoping review aims to identify and synthesize the available research on policy mechanisms designed to address funding bias and COI in biomedical research.</p><p><strong>Methods: </strong>We searched PubMed for peer-reviewed, empirical analyses of policy mechanisms designed to address industry sponsorship of research studies, author industry affiliation, and author COI at any stage of the biomedical research process and published between January 2009 and 28 August 2023. The review identified literature conducting five primary analysis types: (1) surveys of COI policies, (2) disclosure compliance analyses, (3) disclosure concordance analyses, (4) COI policy effects analyses, and (5) studies of policy perceptions and contexts. Most available research is devoted to evaluating the prevalence, nature, and effects of author COI disclosure policies.</p><p><strong>Results: </strong>Six thousand three hundreds eighty five articles were screened, and 81 studies were included. Studies were conducted in 11 geographic regions, with studies of international scope being the most common. Most available research is devoted to evaluating the prevalence, nature, and effects of author COI disclosure policies. This evidence demonstrates that while disclosure policies are pervasive, those policies are not consistently designed, implemented, or enforced. The available evidence also indicates that COI disclosure policies are not particularly effective in mitigating risk of bias or subsequent negative externalities.</p><p><strong>Conclusions: </strong>The results of this review indicate that the COI policy landscape could benefit from a significant shift in the research agenda. The available literature predominantly focuses on a single policy intervention-author disclosure requirements. As a result, new lines of research are needed to establish a more robust evidence-based policy landscape. There is a particular need for implementation research, greater attention to the structural conditions that create COI, and evaluation of policy mechanisms other than disclosure.</p>","PeriodicalId":74682,"journal":{"name":"Research integrity and peer review","volume":"10 1","pages":"6"},"PeriodicalIF":7.2000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076912/pdf/","citationCount":"0","resultStr":"{\"title\":\"Research on policy mechanisms to address funding bias and conflicts of interest in biomedical research: a scoping review.\",\"authors\":\"S Scott Graham, Quinn Grundy, Nandini Sharma, Jade Shiva Edward, Joshua B Barbour, Justin F Rousseau, Zoltan P Majdik, Lisa Bero\",\"doi\":\"10.1186/s41073-025-00164-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Industry funding and author conflicts of interest (COI) have been consistently shown to introduce bias into agenda-setting and results-reporting in biomedical research. Accordingly, maintaining public trust, diminishing patient harm, and securing the integrity of the biomedical research enterprise are critical policy priorities. In this context, a coordinated and methodical research effort is required to effectively identify which policy interventions are most likely to mitigate against the risks of funding bias. Subsequently this scoping review aims to identify and synthesize the available research on policy mechanisms designed to address funding bias and COI in biomedical research.</p><p><strong>Methods: </strong>We searched PubMed for peer-reviewed, empirical analyses of policy mechanisms designed to address industry sponsorship of research studies, author industry affiliation, and author COI at any stage of the biomedical research process and published between January 2009 and 28 August 2023. The review identified literature conducting five primary analysis types: (1) surveys of COI policies, (2) disclosure compliance analyses, (3) disclosure concordance analyses, (4) COI policy effects analyses, and (5) studies of policy perceptions and contexts. Most available research is devoted to evaluating the prevalence, nature, and effects of author COI disclosure policies.</p><p><strong>Results: </strong>Six thousand three hundreds eighty five articles were screened, and 81 studies were included. Studies were conducted in 11 geographic regions, with studies of international scope being the most common. Most available research is devoted to evaluating the prevalence, nature, and effects of author COI disclosure policies. This evidence demonstrates that while disclosure policies are pervasive, those policies are not consistently designed, implemented, or enforced. The available evidence also indicates that COI disclosure policies are not particularly effective in mitigating risk of bias or subsequent negative externalities.</p><p><strong>Conclusions: </strong>The results of this review indicate that the COI policy landscape could benefit from a significant shift in the research agenda. The available literature predominantly focuses on a single policy intervention-author disclosure requirements. As a result, new lines of research are needed to establish a more robust evidence-based policy landscape. There is a particular need for implementation research, greater attention to the structural conditions that create COI, and evaluation of policy mechanisms other than disclosure.</p>\",\"PeriodicalId\":74682,\"journal\":{\"name\":\"Research integrity and peer review\",\"volume\":\"10 1\",\"pages\":\"6\"},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2025-05-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076912/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Research integrity and peer review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s41073-025-00164-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ETHICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research integrity and peer review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41073-025-00164-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ETHICS","Score":null,"Total":0}
引用次数: 0

摘要

背景:行业资助和作者利益冲突(COI)一直被证明会在生物医学研究的议程设置和结果报告中引入偏见。因此,维持公众信任、减少对患者的伤害和确保生物医学研究企业的完整性是关键的政策优先事项。在这方面,需要进行协调和有条不紊的研究工作,以有效地确定哪些政策干预措施最有可能减轻资助偏见的风险。随后,本范围审查旨在确定和综合现有的研究,旨在解决生物医学研究中的资助偏见和COI的政策机制。方法:我们在PubMed检索了2009年1月至2023年8月28日期间发表的生物医学研究过程中任何阶段旨在解决研究的行业赞助、作者行业隶属关系和作者COI的政策机制的同行评议实证分析。该综述确定了进行五种主要分析类型的文献:(1)COI政策调查,(2)披露合规性分析,(3)披露一致性分析,(4)COI政策效果分析,以及(5)政策认知和背景研究。大多数现有的研究都致力于评估作者COI披露政策的普遍性、性质和影响。结果:共筛选了六千三百八十五篇文章,纳入了81项研究。研究在11个地理区域进行,其中国际范围的研究最为普遍。大多数现有的研究都致力于评估作者COI披露政策的普遍性、性质和影响。这一证据表明,虽然披露政策普遍存在,但这些政策的设计、实施或执行并不一致。现有证据还表明,COI披露政策在减轻偏见风险或随后的负面外部性方面并不是特别有效。结论:本综述的结果表明,COI政策格局可以从研究议程的重大转变中受益。现有文献主要集中于单一政策干预——作者披露要求。因此,需要新的研究方向来建立一个更强有力的以证据为基础的政策格局。特别需要进行实施研究,更多地关注产生COI的结构条件,以及评估除披露以外的政策机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Research on policy mechanisms to address funding bias and conflicts of interest in biomedical research: a scoping review.

Background: Industry funding and author conflicts of interest (COI) have been consistently shown to introduce bias into agenda-setting and results-reporting in biomedical research. Accordingly, maintaining public trust, diminishing patient harm, and securing the integrity of the biomedical research enterprise are critical policy priorities. In this context, a coordinated and methodical research effort is required to effectively identify which policy interventions are most likely to mitigate against the risks of funding bias. Subsequently this scoping review aims to identify and synthesize the available research on policy mechanisms designed to address funding bias and COI in biomedical research.

Methods: We searched PubMed for peer-reviewed, empirical analyses of policy mechanisms designed to address industry sponsorship of research studies, author industry affiliation, and author COI at any stage of the biomedical research process and published between January 2009 and 28 August 2023. The review identified literature conducting five primary analysis types: (1) surveys of COI policies, (2) disclosure compliance analyses, (3) disclosure concordance analyses, (4) COI policy effects analyses, and (5) studies of policy perceptions and contexts. Most available research is devoted to evaluating the prevalence, nature, and effects of author COI disclosure policies.

Results: Six thousand three hundreds eighty five articles were screened, and 81 studies were included. Studies were conducted in 11 geographic regions, with studies of international scope being the most common. Most available research is devoted to evaluating the prevalence, nature, and effects of author COI disclosure policies. This evidence demonstrates that while disclosure policies are pervasive, those policies are not consistently designed, implemented, or enforced. The available evidence also indicates that COI disclosure policies are not particularly effective in mitigating risk of bias or subsequent negative externalities.

Conclusions: The results of this review indicate that the COI policy landscape could benefit from a significant shift in the research agenda. The available literature predominantly focuses on a single policy intervention-author disclosure requirements. As a result, new lines of research are needed to establish a more robust evidence-based policy landscape. There is a particular need for implementation research, greater attention to the structural conditions that create COI, and evaluation of policy mechanisms other than disclosure.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
5 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信